On this page
Cord-derived cells are the most widely sold product in this field and among the more studied, which is an unusual combination. Umbilical cord MSC research covers randomised trials in several indications — and one recurring confusion, between cord blood and cord tissue, that a 2026 meta-analysis had to separate explicitly.
What is being studied
Mesenchymal stromal cells isolated from umbilical cord tissue, most often from Wharton’s jelly, the connective tissue surrounding the cord vessels.
These are allogeneic — donor cells — collected with maternal consent after a normal delivery from tissue that would otherwise be discarded as clinical waste.
They are attractive to study for the same reasons they are attractive to sell: young donor age, high proliferative capacity, no harvest procedure, and batches that can be characterised in advance.
There is an ethical dimension worth stating too. The tissue is genuinely surplus, collected after a normal birth with consent, which avoids the objections attaching to embryonic sources. That is a real advantage and it is separate from whether the treatment works.
See cord-derived therapy for what that means practically.
The distinction that keeps being missed
Cord blood is collected from the vessels and is rich in haematopoietic cells — the blood-forming kind used in transplant medicine. Cord tissue is the mesenchymal source.
These have different biology, different uses and separate evidence bases, and both get sold as “umbilical cord stem cells”.
A 2026 meta-analysis in cerebral palsy found it necessary to distinguish them explicitly — An updated meta-analysis of umbilical cord blood to treat cerebral palsy: distinguishing cord blood infusions from mesenchymal stromal cells — which happens when a literature has been pooling two things as one.
A systematic review of controlled studies using cord blood for regenerative therapy identified barriers to assessing that evidence at all — Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy.
Where the randomised evidence sits
Knee osteoarthritis has the clearest study, comparing dosing schedules and finding repeated dosing superior to a single dose — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose.
Diabetic foot ulcers have a prospective randomised controlled study — Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcer.
Autoimmune and rheumatic disease has a 2025 systematic review and meta-analysis — Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases.
And cord-derived extracellular vesicles have been studied in pulmonary fibrosis — Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles — and in knee osteoarthritis — Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis.
How cord cells compare with other sources
A 2024 network meta-analysis compared cell types directly in knee osteoarthritis — Transplantation of three mesenchymal stem cells for knee osteoarthritis, which cell and type are more beneficial?.
That is among the more useful studies in this field, because most patients are choosing between sources rather than between treatment and nothing.
It found differences, which undercuts the common claim that source does not matter — see autologous versus allogeneic.
A network analysis compares indirectly, through each treatment’s trials rather than head to head, so it is weaker than a trial randomising patients between sources. No such trial is widely available, and none is likely while no commercial party benefits from the answer.
The donor screening question
Everything about the safety of a cord-derived product depends on work done before any patient is involved: maternal history, infectious disease screening, assessment of the delivery, and the processing that follows.
Published trials describe these procedures in their methods sections. Commercial preparations often do not, and a patient cannot verify any of it by inspection.
This is the practical difference between a trial product and a purchased one, and it is why release testing is the most useful thing to ask about — see safety studies.
Traceability is the other half of it. A batch that can be traced back to a specific donation, with the screening records attached, is a different proposition from a vial with a label on it.
What remains unsettled
How much the immune question matters. Cord MSCs are described as low-immunogenicity, which is a relative statement rather than an absolute one, and repeat dosing sharpens it considerably — a response generated against a first exposure is waiting for the second.
Whether donor variability affects outcomes — different cords produce different cells, and how much that matters clinically is not well characterised. Trials typically use cells from one or a few donors, so batch-to-batch variation in commercial supply is largely untested territory.
The best dose, interval and number of treatments, which is unsettled across this whole field — see MSC dosage research.
An honest summary
Cord-derived cells have a real and growing evidence base, concentrated in knee osteoarthritis and a few narrow indications, and thin everywhere else.
They are the practical choice for most travelling patients for reasons of logistics rather than superiority, and that is a legitimate basis for the choice as long as it is stated as such rather than dressed up as a clinical judgement about you.
See the research library and the main treatment page.
Frequently asked questions
Is cord blood the same as cord tissue?
No. Cord blood is rich in blood-forming cells; cord tissue is the mesenchymal source. A 2026 meta-analysis had to separate them because they were being pooled.
Where is the evidence strongest?
Knee osteoarthritis by some distance, including a randomised trial comparing dosing schedules, followed by diabetic foot ulcers, which have a prospective randomised controlled study. Elsewhere the evidence thins quickly.
Are donor cells better than my own?
Not established. A 2024 network meta-analysis found differences between cell types, which is more than most claims in this area rest on.
Will donor cells be rejected?
Low immunogenicity is a relative claim, not an absolute one. Serious rejection is not prominent in trial data, and repeat dosing raises the question more sharply.
How do I know the donor was screened?
You cannot verify it yourself. Ask for the screening and release testing to be described, and note whether the answer is specific or general.
Why do clinics prefer cord cells?
Logistics, mainly — no harvest procedure, no weeks of waiting for culture, and consistent batches prepared in advance. That is a perfectly legitimate reason, as long as it is given as the reason rather than presented as a clinical judgement about your case.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.